Foghorn Therapeutics (FHTX) Profit After Tax (2019 - 2026)

Foghorn Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$20.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 6.55% year-over-year to -$20.0 million; the TTM figure through Mar 2026 stood at -$59.6 million (up 26.32% YoY), while the FY2025 annual figure was -$74.3 million, up 14.22% from the prior year.
• Profit After Tax for Q1 2026 stood at -$20.0 million, up from -$21.7 million in the prior quarter.
• The five-year high for Profit After Tax was $80.9 million in Q4 2022, with the low at -$30.5 million in Q1 2023.
• The 5-year median for Profit After Tax is -$20.0 million (2026), against an average of -$8.2 million.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax jumped 377.56% in 2022, then sank 756.42% in 2023.
• Foghorn Therapeutics' Profit After Tax stood at $80.9 million in 2022, then dropped by 6.78% to $75.4 million in 2023, then slumped by 127.42% to -$20.7 million in 2024, then dropped by 4.91% to -$21.7 million in 2025, then advanced by 7.61% to -$20.0 million in 2026.
• Business Quant data shows FHTX's Profit After Tax at -$20.0 million in Q1 2026, -$21.7 million in Q4 2025, and $68000.0 in Q3 2025.